Literature DB >> 824205

Passive immunity against pseudomonas sepsis during granulocytopenia.

L Harvath, B R Andersen, H J Amirault.   

Abstract

Specific passive immunity against Pseudomonas aeruginosa sepsis was assessed in granulocytopenic dogs. Dogs were infused with either normal or antipseudomonas immune plasma 24 h before pseudomonas challenge. They were challenged intravenously with 10(7) serotype 6 P. aeruginosa during granulocytopenia. Treatment was evaluated by observation of survival periods, febrile responses, type 6 pseudomonas antibody titers, and quantitative cultures of blood and tissues. The results demonstrated that passively immunized dogs did not survive infection. Both normal-plasma and immune-plasma recipients had bacteremia at death, with median values of 980 and 470 pseudomonas per ml of blood, respectively. All dogs had marked febrile responses 24 h after pseudomonas challenge and had high concentrations of pseudomonas in their lung tissue at death, with median values of 10(8) pseudomonas per g of wet tissue weight. After plasma infusion, immune-plasma recipients had high concentrations of anti-pseudomonas antibody, with total antibody titers ranging from 256 to 1,024 and a median value of 1,024. These titers were comparable to titers attained in a previous study from our laboratory using active immunization with pseudomonas lipopolysaccharide vaccine, where the median total anti-pseudomonas antibody titer was 2,048. Actively immunized animals, however, were significantly protected against pseudomonas sepsis and had prolonged survival periods and prevention of bacteremia. The present study demonstrates that circulating type-specific antibody is not solely responsible for the protection afforded to granulocytopenic dogs actively immunized against pseudomonas.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 824205      PMCID: PMC415507          DOI: 10.1128/iai.14.5.1151-1155.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  USE OF VACCINE AND HYPERIMMUNE SERUM FOR PROTECTION AGAINST PSEUDOMONAS SEPTICEMIA.

Authors:  I FELLER; A B VIAL; W CALLAHAN; J WALDYKE
Journal:  J Trauma       Date:  1964-07

2.  PSEUDOMONAS INFECTION. TREATMENT WITH IMMUNE PLASMA.

Authors:  D S FEINGOLD; F OSKI
Journal:  Arch Intern Med       Date:  1965-09

3.  The bacterial hemagglutination test for the demonstration of antibodies to Enterobacteriaceae.

Authors:  E A GORZYNSKI; O LUDERITZ; E NETER; O WESTPHAL
Journal:  Ann N Y Acad Sci       Date:  1956-08-10       Impact factor: 5.691

4.  Effect of bone marrow suppression on granulocyte opsonin levels.

Authors:  B R Andersen; K M Debelak-Fehir; R B Epstein
Journal:  Proc Soc Exp Biol Med       Date:  1976-01

5.  Clinical evaluation of Pseudomonas hyperimmune globulin.

Authors:  C E Jones; J W Alexander; M Fisher
Journal:  J Surg Res       Date:  1973-02       Impact factor: 2.192

6.  Pseudomonas vaccine and hyperimmune plasma for burned patients.

Authors:  I Feller; C Pierson
Journal:  Arch Surg       Date:  1968-08

7.  Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.

Authors:  L S Young; D Armstrong
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

8.  Comparative studies on the protective potential of antisera directed against four antigenic preparations from Pseudomonas aeruginosa.

Authors:  L J Johnston; D Syeklocha
Journal:  Can J Microbiol       Date:  1972-10       Impact factor: 2.419

9.  Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. I. Interaction between immunoglobulins, heat-labile serum factors, and phagocytic cells in the killing of bacteria.

Authors:  A B Bjornson; J G Michael
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

10.  Combined pre-immunization and granulocyte transfusion therapy for treatment of pseudomonas septicemia in neutropenic dogs.

Authors:  L Harvath; B R Andersen; A R Zander; R B Epstein
Journal:  J Lab Clin Med       Date:  1976-05
View more
  6 in total

1.  Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI.

Authors:  R Rahner; A Eckhardt; M Duchêne; H Domdey; B U von Specht
Journal:  Infection       Date:  1990 Jul-Aug       Impact factor: 3.553

2.  Effect of type-specific active immunization on the development and progression of experimental Pseudomonas aeruginosa endocarditis.

Authors:  G L Archer; J L Johnston
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

3.  Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

4.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

5.  Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone.

Authors:  S E Greisman; J B DuBuy; C L Woodward
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

6.  Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.